BIOMAT Database Logo BIOMAT Database Logo

Central administration of the neurotensin receptor antagonist, SR48692, modulates diurnal and stress-related hypothalamic-pituitary-adrenal activity. 1997

W B Rowe, and A Nicot, and S Sharma, and D Gully, and C D Walker, and W H Rostène, and M J Meaney, and R Quirion
Department of Psychiatry and Neurology/Neurosurgery, Douglas Hospital Research Center, McGill University, Montreal, Que., Canada.

Previous studies in our laboratory suggest that neurotensin (NT) acts centrally to modulate adrenocorticotropin hormone (ACTH) and corticosterone release. In the present studies, we examined hypothalamic-pituitary-adrenal (HPA) function under basal conditions and during restraint stress following central administration of the highly specific NT receptor antagonist, SR48692. Chronic delivery of SR48692 to the paraventricular nucleus (PVN) of the hypothalamus via indwelling central cannulae attenuated both the diurnal- and stress-induced elevations in HPA activity. Thus, SR48692 decreased the diurnal increase in plasma ACTH and corticosterone during the evening phase of the cycle, but did not affect morning levels. Restraint-induced increases in plasma ACTH and corticosterone levels were also significantly reduced in the SR48692-implanted animals. This suggests that the inhibitory effects of SR48692 were restricted to periods of stimulated HPA activity. A decrease in corticotropin-releasing hormone (CRH)-like immunoreactivity was observed within the PVN following chronic SR48692, and parallel decreases in CRH-like immunoreactivity were observed within the external zone of the median eminence. These findings suggest that endogenous NT serves to increase HPA activity during periods of enhanced stimulation.

UI MeSH Term Description Entries
D007030 Hypothalamo-Hypophyseal System A collection of NEURONS, tracts of NERVE FIBERS, endocrine tissue, and blood vessels in the HYPOTHALAMUS and the PITUITARY GLAND. This hypothalamo-hypophyseal portal circulation provides the mechanism for hypothalamic neuroendocrine (HYPOTHALAMIC HORMONES) regulation of pituitary function and the release of various PITUITARY HORMONES into the systemic circulation to maintain HOMEOSTASIS. Hypothalamic Hypophyseal System,Hypothalamo-Pituitary-Adrenal Axis,Hypophyseal Portal System,Hypothalamic-Pituitary Unit,Hypothalamic Hypophyseal Systems,Hypothalamic Pituitary Unit,Hypothalamo Hypophyseal System,Hypothalamo Pituitary Adrenal Axis,Portal System, Hypophyseal
D008297 Male Males
D008473 Median Eminence Raised area at the infundibular region of the HYPOTHALAMUS at the floor of the BRAIN, ventral to the THIRD VENTRICLE and adjacent to the ARCUATE NUCLEUS OF HYPOTHALAMUS. It contains the terminals of hypothalamic neurons and the capillary network of hypophyseal portal system, thus serving as a neuroendocrine link between the brain and the PITUITARY GLAND. Eminentia Mediana,Medial Eminence,Eminence, Medial,Eminence, Median,Eminences, Medial,Eminentia Medianas,Medial Eminences,Mediana, Eminentia,Medianas, Eminentia
D009496 Neurotensin A biologically active tridecapeptide isolated from the hypothalamus. It has been shown to induce hypotension in the rat, to stimulate contraction of guinea pig ileum and rat uterus, and to cause relaxation of rat duodenum. There is also evidence that it acts as both a peripheral and a central nervous system neurotransmitter.
D009929 Organ Size The measurement of an organ in volume, mass, or heaviness. Organ Volume,Organ Weight,Size, Organ,Weight, Organ
D010286 Paraventricular Hypothalamic Nucleus Nucleus in the anterior part of the HYPOTHALAMUS. Hypothalamic Paraventricular Nucleus,Paraventricular Nucleus,Hypothalamic Nucleus, Paraventricular,Nucleus, Hypothalamic Paraventricular,Nucleus, Paraventricular,Nucleus, Paraventricular Hypothalamic,Paraventricular Nucleus, Hypothalamic
D010913 Pituitary-Adrenal System The interactions between the anterior pituitary and adrenal glands, in which corticotropin (ACTH) stimulates the adrenal cortex and adrenal cortical hormones suppress the production of corticotropin by the anterior pituitary. Pituitary Adrenal System,Pituitary-Adrenal Systems,System, Pituitary-Adrenal,Systems, Pituitary-Adrenal
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D011804 Quinolines
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays

Related Publications

W B Rowe, and A Nicot, and S Sharma, and D Gully, and C D Walker, and W H Rostène, and M J Meaney, and R Quirion
Central administration of the neurotensin receptor antagonist SR48692 attenuates vacuous chewing movements in a rodent model of tardive dyskinesia.
January 2003, Neuroscience,
W B Rowe, and A Nicot, and S Sharma, and D Gully, and C D Walker, and W H Rostène, and M J Meaney, and R Quirion
Effect of the neurotensin receptor antagonist SR48692 on rat blood pressure modulation by neurotensin.
January 1996, Life sciences,
W B Rowe, and A Nicot, and S Sharma, and D Gully, and C D Walker, and W H Rostène, and M J Meaney, and R Quirion
Central administration of neurotensin stimulates hypothalamic-pituitary-adrenal activity. The paraventricular CRF neuron as a critical site of action.
January 1992, Annals of the New York Academy of Sciences,
W B Rowe, and A Nicot, and S Sharma, and D Gully, and C D Walker, and W H Rostène, and M J Meaney, and R Quirion
Inhibition of neurotensin-induced pancreatic carcinoma growth by a nonpeptide neurotensin receptor antagonist, SR48692.
May 1997, Cancer,
W B Rowe, and A Nicot, and S Sharma, and D Gully, and C D Walker, and W H Rostène, and M J Meaney, and R Quirion
Hypothalamic-pituitary-adrenal activity during chronic central administration of interleukin-2.
December 1994, Endocrinology,
W B Rowe, and A Nicot, and S Sharma, and D Gully, and C D Walker, and W H Rostène, and M J Meaney, and R Quirion
The central amygdala modulates hypothalamic-pituitary-adrenal axis responses to systemic interleukin-1beta administration.
January 1999, Neuroscience,
W B Rowe, and A Nicot, and S Sharma, and D Gully, and C D Walker, and W H Rostène, and M J Meaney, and R Quirion
Peripheral administration of an angiotensin II AT(1) receptor antagonist decreases the hypothalamic-pituitary-adrenal response to isolation Stress.
September 2001, Endocrinology,
W B Rowe, and A Nicot, and S Sharma, and D Gully, and C D Walker, and W H Rostène, and M J Meaney, and R Quirion
[Work-related stress and the hypothalamic-pituitary-adrenal axis].
February 2019, Ugeskrift for laeger,
W B Rowe, and A Nicot, and S Sharma, and D Gully, and C D Walker, and W H Rostène, and M J Meaney, and R Quirion
The neurotensin receptor antagonist, SR48692, attenuates the expression of amphetamine-induced behavioural sensitisation in mice.
September 2001, European journal of pharmacology,
W B Rowe, and A Nicot, and S Sharma, and D Gully, and C D Walker, and W H Rostène, and M J Meaney, and R Quirion
Central administration of GPR55 receptor agonist and antagonist modulates anxiety-related behaviors in rats.
April 2015, Fundamental & clinical pharmacology,
Copied contents to your clipboard!